ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2019
Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate.
Article in European heart journal supplements : journal of the European Society of Cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Epidemiology of hyperkalemia among US emergency department patients without end-stage renal disease from 2016 to 2024.Clinical and experimental emergency medicine · 2026Article
- In vivo electrochemical reduction-induced reconfiguration of Prussian blue for metal counterion-free potassium removal in hyperkalemia.Nature communications · 2025Article
- Hyperkalemia management: a multidisciplinary expert panel's perspective on the role of new potassium binders.Heart failure reviews · 2025Review
- Medical Costs and Economic Impact of Hyperkalemia in a Cohort of Heart Failure Patients with Reduced Ejection Fraction.Journal of clinical medicine · 2024Article
- Use of Fludrocortisone for Hyperkalemia in Chronic Kidney Disease Not Yet on Dialysis.Electrolyte & blood pressure : E & BP · 2024Article
- Managing hyperkalemia in patients with heart failure on guideline-directed medical therapy: challenges and opportunities.Internal and emergency medicine · 2024Article
- Understanding and Treatment Strategies of Hypertension and Hyperkalemia in Chronic Kidney Disease.Electrolyte & blood pressure : E & BP · 2023Review
- Compared effectiveness of sodium zirconium cyclosilicate and calcium polystyrene sulfonate on hyperkalemia in patients with chronic kidney disease.Frontiers in medicine · 2023Article
- Inpatient management and post-discharge outcomes of hyperkalemia.Hospital practice (1995) · 2021Article
- Hyperkalemia excursions are associated with an increased risk of mortality and hospitalizations in hemodialysis patients.Clinical kidney journal · 2021Article
- Serum potassium and heart failure: association, causation, and clinical implications.Heart failure reviews · 2021Review
- Management of Acute Kidney Injury in Coronavirus Disease 2019.Advances in chronic kidney disease · 2020Review
- Hyperkalemia in Real-World Patients Under Continuous Medical Care in Japan.Kidney international reports · 2019Article
- Clinical and Economic Burden of Hyperkalemia: A Nationwide Hospital-Based Cohort Study in Japan.Kidney medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperkalaemia is a life-threatening condition, resulting from decreased renal function or dysfunctional homoeostatic mechanisms, often affecting patients with cardiovascular (CV) disease. Drugs such as renin-angiotensin-aldosterone system inhibitors (RAASi) are known to improve outcomes in CV patients but can also cause drug-induced hyperkalaemia. New therapeutic options exist to enhance potassium excretion in these patients. To this aim, we reviewed pharmacological properties and available data on patiromer and sodium zirconium cyclosilicate for the treatment of hyperkalaemia. These agents have been shown in randomized trials to significantly reduce serum potassium in patients with hyperkalaemia on renin-angiotensin-aldosterone system inhibitors. Additional research should focus on their long-term effects/safety profiles and drug-drug interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.